ExodusPoint Capital Management LP raised its stake in Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) by 686.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 182,300 shares of the company's stock after purchasing an additional 159,131 shares during the period. ExodusPoint Capital Management LP owned 0.14% of Surgery Partners worth $3,859,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. KBC Group NV grew its stake in Surgery Partners by 66.1% in the fourth quarter. KBC Group NV now owns 3,962 shares of the company's stock worth $84,000 after purchasing an additional 1,577 shares in the last quarter. MeadowBrook Investment Advisors LLC raised its position in shares of Surgery Partners by 16.6% during the 4th quarter. MeadowBrook Investment Advisors LLC now owns 10,280 shares of the company's stock valued at $218,000 after acquiring an additional 1,460 shares in the last quarter. Empowered Funds LLC bought a new position in Surgery Partners during the fourth quarter worth $245,000. KLP Kapitalforvaltning AS acquired a new position in Surgery Partners in the fourth quarter worth $273,000. Finally, Cannell & Spears LLC bought a new position in shares of Surgery Partners in the 4th quarter worth about $324,000.
Insiders Place Their Bets
In other news, CFO David T. Doherty sold 6,733 shares of Surgery Partners stock in a transaction on Monday, March 10th. The stock was sold at an average price of $24.02, for a total transaction of $161,726.66. Following the transaction, the chief financial officer now directly owns 150,868 shares in the company, valued at approximately $3,623,849.36. This trade represents a 4.27 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Marissa Brittenham sold 3,156 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $24.09, for a total value of $76,028.04. Following the completion of the sale, the insider now directly owns 63,408 shares in the company, valued at $1,527,498.72. This represents a 4.74 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 106,622 shares of company stock worth $2,717,860. 2.30% of the stock is owned by corporate insiders.
Surgery Partners Stock Performance
SGRY stock traded up $0.12 on Friday, reaching $20.99. The company's stock had a trading volume of 815,510 shares, compared to its average volume of 1,099,434. The firm has a fifty day moving average of $23.99 and a two-hundred day moving average of $24.76. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.80 and a quick ratio of 1.66. The company has a market capitalization of $2.68 billion, a P/E ratio of -43.73, a price-to-earnings-growth ratio of 19.21 and a beta of 2.40. Surgery Partners, Inc. has a 52 week low of $19.50 and a 52 week high of $33.97.
Surgery Partners (NASDAQ:SGRY - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.01. The company had revenue of $864.40 million for the quarter, compared to analyst estimates of $828.09 million. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. As a group, analysts predict that Surgery Partners, Inc. will post 0.67 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on SGRY. Royal Bank of Canada reaffirmed an "outperform" rating and set a $35.00 price objective on shares of Surgery Partners in a research report on Tuesday, March 25th. Macquarie dropped their price target on Surgery Partners from $34.00 to $33.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 11th. Finally, Bank of America began coverage on Surgery Partners in a report on Monday, December 16th. They issued a "buy" rating and a $30.00 price target on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, Surgery Partners presently has an average rating of "Moderate Buy" and an average price target of $36.63.
Check Out Our Latest Report on Surgery Partners
Surgery Partners Company Profile
(
Free Report)
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Further Reading
Before you consider Surgery Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surgery Partners wasn't on the list.
While Surgery Partners currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
